Alchemia: First granting of antibody patents

Key patent granted in Japan

28-Jul-2011 - Japan

Alchemia Limited has been granted a new Japanese patent covering its HyACT® platform, which has been shown to increase the effectiveness of cancer drugs. Alchemia’s lead program using this technology, HA-Irinotecan, is about to enter a pivotal Phase III trial for the treatment of colorectal (bowel) cancer.

The patent, JP 2000-593339, entitled “A composition and method for the enhancement of the efficacy of drugs” is the most recent grant in the family of patents protecting Alchemia’s HyACT® technology. Similar protection has already been granted in Australia, New Zealand, Canada, China, Taiwan and a number of European countries including Austria, Belgium, Denmark, France, Germany, Italy, Ireland, Luxembourg, Netherlands, Spain, Switzerland, and the United Kingdom.

“We are very pleased to secure IP protection for the important Japanese market where Irinotecan is widely used in the treatment of colorectal cancer. This patent family is integral in protecting the use of the HyACT® platform in conjunction with small molecule anticancer agents,” said Alchemia CEO Dr Pete Smith. 

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous